Corrigendum: Cemiplimab for advanced cutaneous squamous cell carcinoma in kidney transplant recipients (Néphrologie & Thérapeutique, (2022), 18, 5, (372), 10.1016/j.nephro.2022.07.395)

T. Van Meerhaeghe; J. F. Baurain; O. Bechter; C. Orte Cano; V. Del Marmol; A. Devresse; P. Doubel; M. Hanssens; R. Hellemans; D. Lienard; A. Rutten; B. Sprangers; A. Le Moine; S. Aspeslagh

doi:10.3389/fneph.2022.1129134

Corrigendum: Cemiplimab for advanced cutaneous squamous cell carcinoma in kidney transplant recipients (Néphrologie & Thérapeutique, (2022), 18, 5, (372), 10.1016/j.nephro.2022.07.395)

T. Van Meerhaeghe, J. F. Baurain, O. Bechter, C. Orte Cano, V. Del Marmol, A. Devresse, P. Doubel, M. Hanssens, R. Hellemans, D. Lienard, A. Rutten, B. Sprangers, A. Le Moine, S. Aspeslagh

Research output: Contribution to journal › Comment/debate

Abstract

In the published article, there was a mistake in the Funding statement. The following statement should be removed: “TM declares that this study received funding from Sanofi and Bristol Myers Squibb. The funders were not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication”. The correct statement appears below.

Original language	English
Article number	1129134
Number of pages	2
Journal	Frontiers in nephrology
Volume	2
DOIs	https://doi.org/10.3389/fneph.2022.1129134
Publication status	Published - 2022

Bibliographical note

Funding Information:
TM received research grants from Fonds Erasme, Fonds de la Chirurgie Cardiaque, le Fonds National de Recherche Scientifique Belgium (grant number 40010386), The Belgian Transplant Society Roche grant, The European Society of Organ Transplantation Transplant Fellowship. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.

Funding Information:
In the published article, there was a mistake in the Funding statement. The following statement should be removed: \u201CTM declares that this study received funding from Sanofi and Bristol Myers Squibb. The funders were not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication\u201D. The correct statement appears below.

Funding Information:
TM received research grants from Fonds Erasme, Fonds de la Chirurgie Cardiaque, le Fonds National de Recherche Scientifique Belgium (grant number 40010386), The Belgian Transplant Society Roche grant, The European Society of Organ Transplantation Transplant Fellowship.

Publisher Copyright:
Copyright © 2023 Van Meerhaeghe, Baurain, Bechter, Orte Cano, Del Marmol, Devresse, Doubel, Hanssens, Hellemans, Lienard, Rutten, Sprangers, Le Moine and Aspeslagh.

Keywords

cemiplimab
cutaneous squamous cell carcinoma
immune checkpoint inhibitors
kidney transplant recipients
rejection

Access to Document

10.3389/fneph.2022.1129134

Cite this

Van Meerhaeghe, T., Baurain, J. F., Bechter, O., Orte Cano, C., Del Marmol, V., Devresse, A., Doubel, P., Hanssens, M., Hellemans, R., Lienard, D., Rutten, A., Sprangers, B., Le Moine, A., & Aspeslagh, S. (2022). Corrigendum: Cemiplimab for advanced cutaneous squamous cell carcinoma in kidney transplant recipients (Néphrologie & Thérapeutique, (2022), 18, 5, (372), 10.1016/j.nephro.2022.07.395). Frontiers in nephrology, 2, Article 1129134. https://doi.org/10.3389/fneph.2022.1129134

@article{77d65482d0304681b6e47730dec7a76a,

title = "Corrigendum: Cemiplimab for advanced cutaneous squamous cell carcinoma in kidney transplant recipients (N{\'e}phrologie & Th{\'e}rapeutique, (2022), 18, 5, (372), 10.1016/j.nephro.2022.07.395)",

abstract = "In the published article, there was a mistake in the Funding statement. The following statement should be removed: “TM declares that this study received funding from Sanofi and Bristol Myers Squibb. The funders were not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication”. The correct statement appears below.",

keywords = "cemiplimab, cutaneous squamous cell carcinoma, immune checkpoint inhibitors, kidney transplant recipients, rejection",

author = "{Van Meerhaeghe}, T. and Baurain, {J. F.} and O. Bechter and {Orte Cano}, C. and {Del Marmol}, V. and A. Devresse and P. Doubel and M. Hanssens and R. Hellemans and D. Lienard and A. Rutten and B. Sprangers and {Le Moine}, A. and S. Aspeslagh",

note = "Funding Information: TM received research grants from Fonds Erasme, Fonds de la Chirurgie Cardiaque, le Fonds National de Recherche Scientifique Belgium (grant number 40010386), The Belgian Transplant Society Roche grant, The European Society of Organ Transplantation Transplant Fellowship. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. Funding Information: In the published article, there was a mistake in the Funding statement. The following statement should be removed: \u201CTM declares that this study received funding from Sanofi and Bristol Myers Squibb. The funders were not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication\u201D. The correct statement appears below. Funding Information: TM received research grants from Fonds Erasme, Fonds de la Chirurgie Cardiaque, le Fonds National de Recherche Scientifique Belgium (grant number 40010386), The Belgian Transplant Society Roche grant, The European Society of Organ Transplantation Transplant Fellowship. Publisher Copyright: Copyright {\textcopyright} 2023 Van Meerhaeghe, Baurain, Bechter, Orte Cano, Del Marmol, Devresse, Doubel, Hanssens, Hellemans, Lienard, Rutten, Sprangers, Le Moine and Aspeslagh.",

year = "2022",

doi = "10.3389/fneph.2022.1129134",

language = "English",

volume = "2",

journal = "Frontiers in nephrology",

issn = "2813-0626",

publisher = "Frontiers Media",

}

Van Meerhaeghe, T, Baurain, JF, Bechter, O, Orte Cano, C, Del Marmol, V, Devresse, A, Doubel, P, Hanssens, M, Hellemans, R, Lienard, D, Rutten, A, Sprangers, B, Le Moine, A & Aspeslagh, S 2022, 'Corrigendum: Cemiplimab for advanced cutaneous squamous cell carcinoma in kidney transplant recipients (Néphrologie & Thérapeutique, (2022), 18, 5, (372), 10.1016/j.nephro.2022.07.395)', Frontiers in nephrology, vol. 2, 1129134. https://doi.org/10.3389/fneph.2022.1129134

TY - JOUR

T1 - Corrigendum

T2 - Cemiplimab for advanced cutaneous squamous cell carcinoma in kidney transplant recipients (Néphrologie & Thérapeutique, (2022), 18, 5, (372), 10.1016/j.nephro.2022.07.395)

AU - Van Meerhaeghe, T.

AU - Baurain, J. F.

AU - Bechter, O.

AU - Orte Cano, C.

AU - Del Marmol, V.

AU - Devresse, A.

AU - Doubel, P.

AU - Hanssens, M.

AU - Hellemans, R.

AU - Lienard, D.

AU - Rutten, A.

AU - Sprangers, B.

AU - Le Moine, A.

AU - Aspeslagh, S.

N1 - Funding Information: TM received research grants from Fonds Erasme, Fonds de la Chirurgie Cardiaque, le Fonds National de Recherche Scientifique Belgium (grant number 40010386), The Belgian Transplant Society Roche grant, The European Society of Organ Transplantation Transplant Fellowship. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. Funding Information: In the published article, there was a mistake in the Funding statement. The following statement should be removed: \u201CTM declares that this study received funding from Sanofi and Bristol Myers Squibb. The funders were not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication\u201D. The correct statement appears below. Funding Information: TM received research grants from Fonds Erasme, Fonds de la Chirurgie Cardiaque, le Fonds National de Recherche Scientifique Belgium (grant number 40010386), The Belgian Transplant Society Roche grant, The European Society of Organ Transplantation Transplant Fellowship. Publisher Copyright: Copyright © 2023 Van Meerhaeghe, Baurain, Bechter, Orte Cano, Del Marmol, Devresse, Doubel, Hanssens, Hellemans, Lienard, Rutten, Sprangers, Le Moine and Aspeslagh.

PY - 2022

Y1 - 2022

N2 - In the published article, there was a mistake in the Funding statement. The following statement should be removed: “TM declares that this study received funding from Sanofi and Bristol Myers Squibb. The funders were not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication”. The correct statement appears below.

AB - In the published article, there was a mistake in the Funding statement. The following statement should be removed: “TM declares that this study received funding from Sanofi and Bristol Myers Squibb. The funders were not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication”. The correct statement appears below.

KW - cemiplimab

KW - cutaneous squamous cell carcinoma

KW - immune checkpoint inhibitors

KW - kidney transplant recipients

KW - rejection

UR - http://www.scopus.com/inward/record.url?scp=85205733640&partnerID=8YFLogxK

U2 - 10.3389/fneph.2022.1129134

DO - 10.3389/fneph.2022.1129134

M3 - Comment/debate

AN - SCOPUS:85205733640

SN - 2813-0626

VL - 2

JO - Frontiers in nephrology

JF - Frontiers in nephrology

M1 - 1129134

ER -

Corrigendum: Cemiplimab for advanced cutaneous squamous cell carcinoma in kidney transplant recipients (Néphrologie & Thérapeutique, (2022), 18, 5, (372), 10.1016/j.nephro.2022.07.395)

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Cite this